Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Antimicrobial Effectiveness

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

Development of Antibiotic Resistance

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...

Coordination of Gene Expression Processes in Bacteria

Coordination of Gene Expression Processes in Bacteria

The DNA replication, transcription, and translation processes are intricately coupled in bacteria, allowing efficient gene expression and rapid protein synthesis. While this physical and functional coordination is advantageous, it introduces challenges that bacteria overcome through specific regulatory mechanisms.Coupling of Replication, Transcription, and TranslationThe coupling of replication, transcription, and translation is a hallmark of bacterial gene expression. As the replisome unwinds...

Antibiotic Selection

Antibiotic Selection

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Feasibility, accuracy, and effect of a rapid point-of-care serological test (SeroSelectTB) to identify presumptive pulmonary TB patients for confirmatory testing in Ethiopia, South Africa, and Tanzania: a multicenter, open-label, parallel-group, randomized, controlled trial.

EClinicalMedicine·2026

Same author

When the whole exceeds the sum of its parts: Squeezing greater cumulative benefit from cross-technology partnerships in bacterial infection.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Same author

Strengthening antimicrobial resistance governance in Europe: a coordinated one health approach.

The Lancet regional health. Europe·2026

Same author

From 60 Causes to 10 Solutions Against Antibiotics Shortages in Sweden: Platinea's Approach to Developing Policy Interventions.

Antibiotics (Basel, Switzerland)·2025

Same author

Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance.

Nature communications·2025

Same author

Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements.

BMJ (Clinical research ed.)·2025

Search research articles

Related Experiment Video

Updated: Jan 9, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Antibiotic Pipeline Coordinators.

Enrico Baraldi¹, Olof Lindahl¹, Miloje Savic¹

¹Enrico Baraldi, Ph.D., is Professor of Industrial Engineering and Management at Uppsala University. His research focuses on innovation studies, business strategy, industrial marketing and purchasing, and commercialization of science. Olof Lindahl, Ph.D., is an Assistant Professor of International Business at Uppsala University. His research focuses on multinational corporations, managing innovation, and strategy. Miloje Savic, Ph.D., is a senior adviser on public health and antimicrobial resistance at the Norwegian Institute of Public Health. David Findlay, M.B.A., was a Global Commercial Director for anti-infectives at GSK and has a B.Sc. in Experimental Psychology from Reading University and an M.B.A. specializing in international business strategy from the University of Bradford's Management Centre. Christine Årdal, Ph.D., is a Senior Advisor at the Norwegian Institute of Public Health, co-lead for the DRIVE-AB research project, and co-lead on the European Union's Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections. Her research focuses are within antibiotic and neglected disease policy, particularly in regards to innovation and access.

The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics

|August 28, 2018

Summary

This summary is machine-generated.

The World Health Organization identified priority antibiotic-resistant bacteria. A pipeline coordinator can help guide research and development, especially for less commercially attractive antibiotics.

More Related Videos

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Related Experiment Videos

Last Updated: Jan 9, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Area of Science:

Microbiology and Infectious Diseases
Pharmaceutical Research and Development
Global Health Policy

Background:

Antibiotic resistance poses a significant global health threat, necessitating new drug development.
The World Health Organization (WHO) has prioritized specific antibiotic-resistant bacteria to focus research efforts.
The current antibacterial research and development (R&D) pipeline shows disparities in private sector investment, with some priority pathogens receiving less attention.

Purpose of the Study:

To highlight the WHO's global priority list of antibiotic-resistant bacteria.
To analyze the current state of the antibacterial R&D pipeline concerning private sector investment.
To introduce the concept and role of a 'pipeline coordinator' in addressing R&D gaps for priority pathogens.

Main Methods:

Review of the World Health Organization's global priority list of antibiotic-resistant bacteria.
Analysis of the existing antibacterial drug development pipeline, focusing on investment trends.
Conceptual framework development for a 'pipeline coordinator' role.

Main Results:

The WHO list identifies critical pathogens requiring urgent R&D.
Certain priority pathogens are less attractive for private sector investment, leading to pipeline imbalances.
A pipeline coordinator can strategically support R&D across all priority pathogens.

Conclusions:

Targeted R&D is crucial for combating antibiotic resistance.
Addressing market failures in antibiotic development requires innovative financing and coordination.
Pipeline coordinators are essential for ensuring comprehensive R&D coverage of WHO priority pathogens.